Aging and neurodegenerative diseases share common hallmarks, including mitochondrial
dysfunction and protein aggregation. Moreover, one of the major issues of the demographic …

Parkinson disease (PD) is characterized by loss of the A9 nigral neurons that provide
dopaminergic innervation to the striatum. This discovery led to the successful instigation of …

Midbrain dopaminergic (mDA) neuron development has been an intense area of research
during recent years. This is due in part to a growing interest in regenerative medicine and …

Generation of precisely patterned neural cells from human pluripotent stem cells (hPSCs) is
instrumental in developing disease models and stem cell therapies. Here, we provide a …

The potential to generate virtually any differentiated cell type from embryonic stem cells
(ESCs) offers the possibility to establish new models of mammalian development and to …

The future of safe cell-based therapy rests on overcoming teratoma/tumor formation, in
particular when using human pluripotent stem cells (hPSCs), such as human embryonic …

In Parkinson's disease (PD), there are currently no effective therapies to prevent or slow
down disease progression. Cell replacement therapy using human pluripotent stem cell …

Human embryonic stem cells (hESCs) have been proposed as a source of dopamine (DA)
neurons for transplantation in Parkinson's disease (PD). We have investigated the effect of in …

Neuro 2A (N2a) is a mouse neural crest-derived cell line that has been extensively used to
study neuronal differentiation, axonal growth and signaling pathways. A convenient …

Parkinson disease (PD) involves the selective loss of midbrain dopamine (mDA) neurons
and is a possible target disease for stem cell–based therapy. Human induced pluripotent …